Super-charging Your Immune Armies Within
to Wipe Out Cancer and Viruses
AVM Biotechnology's AVM0703
Should be the First Choice
for Cancer Treatment
Find Out More
Find Out More AVM Biotechnology's AVM0703
is Ready to Fight COVID-19
Read the Press Release Here AVM Biotechnology has FDA Approval
for Clinical Trials for Promising
New Cancer Treatment

About AVM Biotechnology

AVM Biotechnology was founded in 2008 by Dr. Theresa Deisher, Ph.D. With over 30 years of successful pharmaceutical research experience and holding over 35 patents, Dr. Deisher leads a team of scientists in researching game-changing stem cell technologies. Our lead molecule, AVM0703, received FDA approval in April 2020 to proceed with Phase I/II clinical trials for the treatment of lymphoid malignancies.  AVM Biotechnology’s research shows that AVM0703 may also be an effective therapeutic treatment against viruses, including COVID-19.  The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19.  To further that research, AVM Biotechnology has filed with the FDA for the approval to proceed with clinical trials against this deadly virus. 

About AVM0703

Supercharged Natural Killer T-cells

NKT cells love to kill cancer, viruses and bacteria, and provide long-term immunity. These are like an elite special forces unit.

Supercharged Cytotoxic T Cells

Cytotoxic T cells are a bridge between innate and adaptive immunity. They act quickly, while also providing long term effects.

Supercharged CD11b + Dendritic Cells

Dendritic ‘Pac-Man’ cells engulf the dead and dying matter, and form a partnership with the NKT cells, alerting them to infections like early warning scouts

Our Mission Statement

We at AVM Biotechnology seek to improve the availability and level of care for patients around the world. Our mission is to deliver drugs that work fast and are safe, effective, affordable, and available. At AVM, we strive to develop products that improve outcomes without additional suffering because we believe that side effects from the treatments of cancers or infections should never be worse than the diseases themselves.

AVM Team

Scientific and Clinical Advisory Board

Dr. Frank Buttgereit

Scientific & Clinical Advisor

Dr. Gordon Roble

Scientific & Clinical Advisor

Gustavo Mahler, Ph.D.

Scientific & Clinical Advisor

Dr. William Matsui

Scientific & Clinical Advisor

John Harlan M.D.

Scientific & Clinical Advisor

Dr. Ed Loniewski

Investor and Principle Investigator

AVM Board of Managers

Theresa Deisher, Ph.D.

Founder & CEO/ Chairman of AVM Board

Michael J. Bernard

AVM Advisor & Chief Tax Officer @ Vertex Inc.

Research Team

Yumna Zahid, M.S.

Senior Research Scientist

Kendra Poulin

Research Scientist

Stephanie Lee-Diaz

Research Scientist

Vaishnavi Parthasarathy

Research Scientist

Colleen Rylatt

Research Scientist

Admin Team

Terry (Terrence) Kopp

VP of Investor Relations

Neil O’Connor, MBA

Chief Financial Officer

Michael Anderson

President & Chief Administrative Officer

Shruti Haridas

Business Analyst